Dublin, Dec. 30, 2021 (GLOBE NEWSWIRE) -- The "Neurodegenerative Disorder Therapeutics Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
This report provides strategists, marketers and senior management with the critical information they need to assess the global neurodegenerative disorder therapeutics market.
This report focuses on the neurodegenerative disorder therapeutics market which is experiencing strong growth. The report gives a guide to the neurodegenerative disorder therapeutics market which will be shaping and changing our lives over the next ten years and beyond, including the market's response to the challenge of the global pandemic.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:
Where is the largest and fastest growing market for neurodegenerative disorder therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Neurodegenerative Disorder Therapeutics market global report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider neurodegenerative disorder therapeutics market, and compares it with other markets.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
- Market segmentations break down market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
- The neurodegenerative disorder therapeutics market section of the report gives context. It compares the neurodegenerative disorder therapeutics market with other segments of the neurodegenerative disorder therapeutics market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, neurodegenerative disorder therapeutics indicators comparison.
Major players in the neurodegenerative disorder therapeutics market are Biogen, Pfizer, Novartis, Sanofi, Teva Pharmaceutical, UCB, Hoffmann- La Roche Ltd, ACADIA Pharmaceuticals Inc., Lundeck A/S and Boehringer Ingeiheim International GmbH.
The global neurodegenerative disorder therapeutics market is expected to grow from $14.08 billion in 2020 to $15.19 billion in 2021 at a compound annual growth rate (CAGR) of 7.9%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $20.15 billion in 2025 at a CAGR of 7%.
The neurodegenerative disorder therapeutics market consists of sales of neurodegenerative disorder therapeutics products and related services for neurodegenerative disorders. Neurodegenerative disorder is a range of incurable conditions that primarily affect the neurons of human brain and results in progressive degeneration or death of nerve cells. The neurodegenerative disorder therapeutics deals with the manufacturing and development of drugs and treatment that stops or slows down the neurodegenerative processes of diseases such as Parkinson's, Alzheimer's, Huntington's and other neurodegenerative disorders.
The neurodegenerative disorder therapeutics market covered in this report is segmented by indication type into Parkinson's disease, Alzheimer's disease, multiple sclerosis, Huntington disease, other indications. It is also segmented by drug type into n- methyl- d- aspartate receptor, selective serotonin reuptake inhibitor, dopamine inhibitors, others and by distribution into hospital pharmacy, retail pharmacy, online pharmacy.
The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
High rates of failure in clinical trials and research and development (R&D) have always been a major challenge in the neurodegenerative disorder therapeutics market. Companies are continuously investing in R&D to develop treatments for neurodegenerative diseases but currently very few treatments are approved for neurodegenerative disorders. According to a study in 2019, there are officially 112 new molecular entities in Alzheimer's disease (AD) clinical trials, although there are 3558 in cancer trials.
For instance, 12 of the 42 (28 per cent) drugs certified by the US Food and Drug Administration (FDA) were oncology therapies, this compares with 0% of AD drugs in production. This failure entitled Alzheimer's disease drugs to the highest rates of failure at 99.6% when compared to any other disease, including cancer, which has a failure rate at 81%. Moreover, as reported by The New England Journal of Medicine, no new drug has been approved by the Food and Drug Administration (FDA) to treat Alzheimer's disease since 2013. The low rate of approval of neurodegenerative therapeutics has a negative impact on the market, hindering the growth of the market.
Increased prevalence of neurodegenerative among the global population contributes to the growth of neurodegenerative disorder therapeutics market. The increase in the number of geriatric population, attributes to the increased prevalence of neurodegenerative disorders.
According to World Population Prospects, the number of people above 60 years of age increased to 2.1 billion in 2050 and it is expected that people aged over 80 years will triple to 425 million in 2050. According to the Alzheimer's Association, around 5.8 million Americans are suffering with Alzheimer's disease and this number is projected to rise to around 14 million by 2050. The increased prevalence of neurodegenerative diseases among the ageing population increases the demand for neurodegenerative disorder therapeutics thereby driving the market.
Manufacturers of neurodegenerative disorder therapeutics are undergoing various strategic partnerships with government and non- government organizations to discover and develop therapeutics for a range of neurodegenerative diseases. The companies in the neurodegenerative disorder therapeutics market are also increasing their collaboration with other players in the market in order to increase their capabilities for research and development activities in order to develop new and more effective therapeutic solutions to treat neurodegenerative disorders.
The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Key Topics Covered:
1. Executive Summary
2. Neurodegenerative Disorder therapeutics Market Characteristics
3. Neurodegenerative Disorder therapeutics Market Trends and Strategies
4. Impact Of COVID-19 On Neurodegenerative Disorder therapeutics
5. Neurodegenerative Disorder therapeutics Market Size and Growth
5.1. Global Neurodegenerative Disorder therapeutics Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of the Market
5.1.2. Restraints On the Market
5.2. Global Neurodegenerative Disorder therapeutics Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of the Market
5.2.2. Restraints On the Market
6. Neurodegenerative Disorder therapeutics Market Segmentation
6.1. Global Neurodegenerative Disorder therapeutics Market, Segmentation by Indication Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
- Parkinson's Disease
- Alzheimer's Disease
- Multiple Sclerosis
- Huntington Disease
- Other Indication Types
6.2. Global Neurodegenerative Disorder therapeutics Market, Segmentation by Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
- N- methyl- D- aspartate Receptor
- Selective Serotonin Reuptake Inhibitor
- Dopamine Inhibitors
- Other Drug Types
6.3. Global Neurodegenerative Disorder therapeutics Market, Segmentation by Distribution, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
7. Neurodegenerative Disorder therapeutics Market Regional and Country Analysis
7.1. Global Neurodegenerative Disorder therapeutics Market, Split by Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Neurodegenerative Disorder therapeutics Market, Split by Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
For more information about this report visit https://www.researchandmarkets.com/r/ntlo4i
